FDA Inspection 1010162 — Mark Glazebrook, MD, PhD
The FDA completed an inspection of Mark Glazebrook, MD, PhD on April 13, 2017 in Halifax. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Devices.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- April 13, 2017
- Fiscal Year
- 2017
- Product Type
- Devices
- Project Area
- Bioresearch Monitoring
- Location
- Halifax (Canada)
Additional Details
Clinical Investigator (CI)